Building T cell engagers that target multiple cancer signals | Founder & CEO Deck Bio | Stanford Immunology PhD
Cambridge, MA
- Tweets 136
- Following 659
- Followers 472
- Likes 791
Pinned Tweet
Cancer isn’t driven by a single target.
Our therapies aren’t either.
We’re at #AACR26 this morning presenting DBXO-1, a multi-pMHC targeted T cell engager from Deck Bio.
📍 Poster #1632 (Board 24), Section 10
#TCellEngagers #ImmunoOncology #TumorHeterogeneity
179
$MRNA with the single most hilarious possible outcome in this study. EFS HR 0.58. Down the the hundredth, EXACTLY what *NEO*-adjuvant treatment with pembro yielded against adjuvant pembro (the nerfed comparator $MRNA studied against) in SWOG S1801.
What does this mean in English? $MRNA’s drug is showing the exact same benefit versus adjuvant pembrolizumab as NEOadjuvant pembrolizumab did.
Even more simply? If you just give patients a few doses of the pembrolizumab BEFORE you cut their cancer out, you do what $MRNA does for you, except with just the free tumor that’s already inside your body. No need to pay for this $400K drug.
And this makes rational sense, right? The whole point of $MRNA’s vaccine is to produce stuff that looks like the tumor.
You know what looks A LOT like the tumor does? THE FREAKING TUMOR!!!!!!
Absolutely poetic that $MRNA produced the EXACT HR benefit as neoadjuvant pembro did. Truly, the most hilarious possible outcome.
Now can we move on from this bullshit? $MRK and $MRNA should feel free to study their vaccine against the REAL standard of care now - NEOadjuvant immunotherapy.
From my perspective, this has been total fugaze, and an amateurish pump and dump worthy of much lesser enterprises.
73
83
581
224,954
Jack Silberstein retweeted
Landmark day in small cell lung cancer, addition of tarlatamab (a new immunotherapy) to standard durvalumab maintenance improves overall survival for one of the hardest cancers to treat, full results awaited #lcsm amgen.com/newsroom/press-rel…
4
24
86
9,263
Jack Silberstein retweeted
RAS(ON)i daraxonrasib in pretreated RAS mutant (non G12C) lung cancer, high grade tox in 54% incl 2.9% deaths. Tumor responses in 31-37% of pts, PFS 8.3m. So far not the breakthrough in lung cancer that it has been in pancreatic
cancer #lcsm
In a phase 1–2 study of daraxonrasib, 54% of patients with RAS-mutant non–small-cell lung cancer had grade 3 or higher adverse events, mainly pneumonia, diarrhea, and rash; more than 30% of patients had a response. Full study results: nej.md/4h0GHUW
ALT A graph showing progression-free survival in patients with RAS-mutant and RAS G12–mutant NSCLC who had received previous first- or second-line platinum-based chemotherapy and anti–programmed cell death 1 or anti–programmed cell death ligand 1 therapy but not docetaxel and received 160 to 220 mg of daraxonrasib.
7
22
105
51,753
Jack Silberstein retweeted
Sig Vedotin fails against docetaxel in second line lung cancer. Major ADC number 3 to fail here recently after datodxd and sac-govitecan, different payloads same story…NSCLC is not SCLC, breast or bladder cancer businesswire.com/news/home/2…
6
18
50
5,720
Jack Silberstein retweeted
🧬 Could the future of cancer immunotherapy be multi-target instead of single-target?
In this fascinating @ProgressPotent1 conversation, I sit down with Dr. Jack Silberstein - @Jack_Silb - Founder and CEO of Deck Bio, to explore a next-generation approach to T cell engager therapies designed specifically for solid tumors.
We discuss:
🔹 Why traditional T cell engagers succeeded in blood cancers but struggled in solid tumors;
🔹 The biology of peptide-MHC (pMHC) targeting;
🔹 Tumor heterogeneity and antigen escape;
🔹 Multi-target immune recognition;
🔹 Deck Bio’s AACR 2026 preclinical data;
🔹 The future of engineered TCR therapies and combinatorial cancer targeting;
Deck Bio’s core thesis is fascinating:
👉 Cancer may not be a “single antigen” disease - and next-generation immunotherapies may need to recognize patterns of tumor identity instead of one marker at a time.
A deep dive into one of the most technically ambitious areas in modern oncology and immune engineering.
#CancerResearch #Immunotherapy #DeckBio #TCellEngagers #Biotech #AACR2026 #Oncology #TCRTherapy #PrecisionMedicine #CancerInnovation
@russopartners
2
5
168
Jack Silberstein retweeted
🧬 Could the future of cancer immunotherapy be multi-target instead of single-target?
In this fascinating @ProgressPotent1 conversation, I sit down with Dr. Jack Silberstein - @Jack_Silb - Founder and CEO of Deck Bio, to explore a next-generation approach to T cell engager therapies designed specifically for solid tumors.
We discuss:
🔹 Why traditional T cell engagers succeeded in blood cancers but struggled in solid tumors;
🔹 The biology of peptide-MHC (pMHC) targeting;
🔹 Tumor heterogeneity and antigen escape;
🔹 Multi-target immune recognition;
🔹 Deck Bio’s AACR 2026 preclinical data;
🔹 The future of engineered TCR therapies and combinatorial cancer targeting;
Deck Bio’s core thesis is fascinating:
👉 Cancer may not be a “single antigen” disease - and next-generation immunotherapies may need to recognize patterns of tumor identity instead of one marker at a time.
A deep dive into one of the most technically ambitious areas in modern oncology and immune engineering.
Watch now - piped.video/watch?v=4VE2AS-A…
#CancerResearch #Immunotherapy #DeckBio #TCellEngagers #Biotech #AACR2026 #Oncology #TCRTherapy #PrecisionMedicine #CancerInnovation @russopartners
2
5
143
Jack Silberstein retweeted
As presented at the 2026 ASCO Annual Meeting: A phase 1a trial of IMA401, a new bispecific TCR-based T cell engager that binds a MAGEA4/8 peptide, has encouraging safety and a preliminary efficacy signal in patients with head & neck cancers and melanoma. dlvr.it/TSpL57
7
22
4,665
Jack Silberstein retweeted
Helping to record a couple of episodes in our @MassBio Kendall Square studio to cap off the year.
2
23
5,050
Jack Silberstein retweeted
I am excited to share our @NatureComms paper describing the structure of #LAG3 bound to MHC-II. This project was carried out by @SuperMQQ et al at @MoffittResearch and provides new insights into the mechanism by which LAG3 suppresses T cell activation. nature.com/articles/s41467-0…
10
28
120
9,001
Jack Silberstein retweeted
Recruitment! We are looking for a candidate for the lab (postdoc or scientist) with experience in yeast and/or phage display to work on some cool bioengineering projects for immunotherapy development! Please reach out if interested! Science friends, please retweet!
3
39
87
14,839
I'm excited to share our work "Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function" that's now out in PNAS! 1/3
Link to paper: pnas.org/doi/10.1073/pnas.23…
Link to press release: news.stanford.edu/2024/03/11…
2
6
25
2,912
Using our solved structure of LAG-3 dimer, we mutated the dimer interface to reveal dimerization as key to LAG-3 function. More importantly, we uncovered the mechanism of the LAG-3 antibody C9B7W, which binds a distinct site from clinical LAG-3 antibodies... 2/3
1
160
Jack Silberstein retweeted
Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. rdcu.be/c7avS
24
77
314
68,434
Jack Silberstein retweeted
After a long day of clinic, #ChatGPT helped me write✍️ a letter of medical necessity to an insurance company.😅
🤗🤖 @OpenAI ✅👍🏾
#Cancer #Doctor #PatientCare #MedTwitter
20
37
268
72,232
Jack Silberstein retweeted
Authored by Andrew G. Soerens et al, we show that #Tcells are capable of proliferating in response to iterative stimulation for over 10yrs! And produce enough progeny to occupy a volume 30,000x the Earth's volume! @Nature nature.com/articles/s41586-0…
35
380
1,356
545,530
Jack Silberstein retweeted
Here’s the Atlas Venture 2022 Year In Review.
This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on Atlas piped.video/LONM9ekseJ4
12
49
274